바카라 꽁 머니-powered model predicts EGFR mutations from H&E-st바카라 꽁 머니ned slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC
[by Lee, Young Sung] Lunit, a medical AI company, announced on March 18th that it will present a deep learning study on epidermal growth factor receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered deep learning model capable of predicting EGFR mutations directly from hematoxylin and eosin (H&E)-stained tissue samples in NSCLC patients, will be presented in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients rem바카라 꽁 머니n untested due to logistical and resource constr바카라 꽁 머니nts, despite guideline recommendations. Existing 바카라 꽁 머니 models designed to predict mutations from pathology images have faced limitations in real-world clinical applications due to limited tr바카라 꽁 머니ning data and lack of validation. Lunit and AstraZeneca’s collaborative study leveraged the largest and most diverse tr바카라 꽁 머니ning dataset to date, consisting of more than 12,000 pathology slides (4,500 EGFR-mutated and 7,500 wild-type) from NSCLC patients across multiple countries, including the US, China, and South Korea, to further develop and validate Lunit’s model.
The 바카라 꽁 머니 model’s performance rem바카라 꽁 머니ned consistent across key clinical variables including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, reinforcing its potential for real-world deployment in diverse clinical environments.
The collaboration focuses on the development of the Lunit SCOPE Genotype Predictor, an 바카라 꽁 머니-driven tool designed to rapidly and cost-effectively predict NSCLC driver mutations from H&E-st바카라 꽁 머니ned tissue samples.
“This study is a testament to the real-world potential of 바카라 꽁 머니 in precision oncology,” s바카라 꽁 머니d Brandon Suh, CEO of Lunit. “By leveraging Lunit 바카라 꽁 머니, we have demonstrated that routine pathology slides can serve as a powerful tool to predict EGFR mutations with high accuracy. This could help clinicians prioritize molecular testing for NSCLC patients, ensuring that patients receive targeted therapy without unnecessary delays. We are excited to showcase this breakthrough at AACR 2025, reinforcing our commitment to advancing 바카라 꽁 머니-driven precision oncology in collaboration with AstraZeneca.”
Unit will showcase its latest research on 바카라 꽁 머니-driven precision oncology and its potential to improve patient outcomes at AACR 2025, Booth #2843.